RedHill Biopharma annual r&d spending
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
RedHill Biopharma R&D Spending Growth & History (RDHL)
RedHill Biopharma's r&d spending was $2.0M for fiscal 2025.
View full RedHill Biopharma company overviewRedHill Biopharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.0M | $435,000 | +27.39% |
| 2024 | 2024-12-31 | $1.6M | −$1.9M | −54.99% |
| 2023 | 2023-12-31 | $3.5M | −$3.8M | −51.53% |
| 2022 | 2022-12-31 | $7.3M | −$22.2M | −75.32% |
| 2021 | 2021-12-31 | $29.5M | $13.0M | +78.87% |
| 2020 | 2020-12-31 | $16.5M | −$928,000 | −5.33% |
| 2019 | 2019-12-31 | $17.4M | −$7.4M | −29.94% |
| 2018 | 2018-12-31 | $24.9M | −$8.1M | −24.59% |
| 2017 | 2017-12-31 | $33.0M | $7.7M | +30.62% |
| 2016 | 2016-12-31 | $25.2M | $7.5M | +42.03% |
| 2015 | 2015-12-31 | $17.8M | — | — |
RedHill Biopharma quarterly r&d spending
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2022 | 2022-06-30 | $1.5M | −$8.9M | −85.75% |
| Q2 2021 | 2021-06-30 | $10.3M | $7.1M | +221.34% |
| Q2 2020 | 2020-06-30 | $3.2M | −$3.8M | −53.90% |
| Q2 2019 | 2019-06-30 | $7.0M | $928,000 | +15.35% |
| Q2 2018 | 2018-06-30 | $6.0M | −$2.4M | −28.34% |
| Q2 2017 | 2017-06-30 | $8.4M | — | — |
RedHill Biopharma r&d spending trends
Over the last five fiscal years, RedHill Biopharma's r&d spending decreased from $16.5M to $2.0M, a change of −$14.5M. The latest reported quarter, Q2 2022, shows $1.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RedHill Biopharma source filings ↗